Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. (May 2014)
- Record Type:
- Journal Article
- Title:
- Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. (May 2014)
- Main Title:
- Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation
- Authors:
- Hassan, Samia
Eldeeb, Khalil
Millns, Paul J
Bennett, Andrew J
Alexander, Stephen P H
Kendall, David A - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12615-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Microglial cells are important mediators of the immune response in the CNS. The phytocannabinoid, cannabidiol (CBD), has been shown to have central anti‐inflammatory properties, and the purpose of the present study was to investigate the effects of CBD and other phytocannabinoids on microglial phagocytosis.</p> </sec> <sec id="bph12615-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Phagocytosis was assessed by measuring ingestion of fluorescently labelled latex beads by cultured microglial cells. Drug effects were probed using single‐cell Ca<sup>2+</sup> imaging and expression of mediator proteins by immunoblotting and immunocytochemistry.</p> </sec> <sec id="bph12615-sec-0003" sec-type="section"> <title>Key Results</title> <p>CBD (10 μM) enhanced bead phagocytosis to 175 ± 7% control. Other phytocannabinoids, synthetic and endogenous cannabinoids were without effect. The enhancement was dependent upon Ca<sup>2+</sup> influx and was abolished in the presence of EGTA, the Ca<sup>2+</sup> channel inhibitor SKF96365, the transient receptor potential (TRP) channel blocker ruthenium red, and the TRPV1 antagonists capsazepine and AMG9810. CBD produced a sustained increase in intracellular Ca<sup>2+</sup> concentration in BV‐2 microglia and this was abolished by ruthenium red. CBD<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12615-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Microglial cells are important mediators of the immune response in the CNS. The phytocannabinoid, cannabidiol (CBD), has been shown to have central anti‐inflammatory properties, and the purpose of the present study was to investigate the effects of CBD and other phytocannabinoids on microglial phagocytosis.</p> </sec> <sec id="bph12615-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Phagocytosis was assessed by measuring ingestion of fluorescently labelled latex beads by cultured microglial cells. Drug effects were probed using single‐cell Ca<sup>2+</sup> imaging and expression of mediator proteins by immunoblotting and immunocytochemistry.</p> </sec> <sec id="bph12615-sec-0003" sec-type="section"> <title>Key Results</title> <p>CBD (10 μM) enhanced bead phagocytosis to 175 ± 7% control. Other phytocannabinoids, synthetic and endogenous cannabinoids were without effect. The enhancement was dependent upon Ca<sup>2+</sup> influx and was abolished in the presence of EGTA, the Ca<sup>2+</sup> channel inhibitor SKF96365, the transient receptor potential (TRP) channel blocker ruthenium red, and the TRPV1 antagonists capsazepine and AMG9810. CBD produced a sustained increase in intracellular Ca<sup>2+</sup> concentration in BV‐2 microglia and this was abolished by ruthenium red. CBD rapidly increased the expression of TRPV2 and TRPV1 proteins and caused a translocation of TRPV2 to the cell membrane. Wortmannin blocked CBD enhancement of BV‐2 cell phagocytosis, suggesting that it is mediated by PI3K signalling downstream of the Ca<sup>2+</sup> influx.</p> </sec> <sec id="bph12615-sec-0004" sec-type="section"> <title>Conclusions and Implications</title> <p>The TRPV‐dependent phagocytosis‐enhancing effect of CBD suggests that pharmacological modification of TRPV channel activity could be a rational approach to treating neuroinflammatory disorders involving changes in microglial function and that CBD is a potential starting point for future development of novel therapeutics acting on the TRPV receptor family.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 171:Number 9(2014:May)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 171:Number 9(2014:May)
- Issue Display:
- Volume 171, Issue 9 (2014)
- Year:
- 2014
- Volume:
- 171
- Issue:
- 9
- Issue Sort Value:
- 2014-0171-0009-0000
- Page Start:
- 2426
- Page End:
- 2439
- Publication Date:
- 2014-05
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.12615 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3860.xml